<iati-activities version="2.03">
 <iati-activity default-currency="USD" dstore:dataset="cepi-998" dstore:index="1" hierarchy="1" humanitarian="0" iati-activities:generated-datetime="2020-03-24T10:30:24+00:00" iati-activities:version="2.03" last-updated-datetime="2020-03-24T10:30:24+00:00" xml:lang="EN" xmlns:dstore="http://d-portal.org/xmlns/dstore" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <activity-date iso-date="2016-08-30" type="2">
   <narrative xml:lang="EN">Company created in 2016. First disbursement to awardees made in 2018</narrative>
  </activity-date>
  <activity-scope code="1"></activity-scope>
  <activity-status code="2"></activity-status>
  <budget status="1" type="1">
   <period-end iso-date="2019-12-31"></period-end>
   <period-start iso-date="2019-01-01"></period-start>
   <value currency="USD" value-date="2018-12-31"></value>
  </budget>
  <budget status="1" type="2">
   <period-end iso-date="2020-12-31"></period-end>
   <period-start iso-date="2020-01-01"></period-start>
   <value currency="USD" value-date="2020-03-09"></value>
  </budget>
  <budget status="1" type="2">
   <period-end iso-date="2021-12-31"></period-end>
   <period-start iso-date="2021-01-01"></period-start>
   <value currency="USD" value-date="2020-03-09"></value>
  </budget>
  <budget status="1" type="2">
   <period-end iso-date="2022-12-31"></period-end>
   <period-start iso-date="2022-01-01"></period-start>
   <value currency="USD" value-date="2020-03-09"></value>
  </budget>
  <budget status="1">
   <period-end iso-date="2023-12-31"></period-end>
   <period-start iso-date="2023-01-01"></period-start>
   <value currency="USD" value-date="2019-12-31"></value>
  </budget>
  <contact-info type="1">
   <email>secretariat@cepi.net</email>
   <mailing-address>
    <narrative xml:lang="EN">Marcus Thranes gate 2, 0473 Oslo</narrative>
   </mailing-address>
   <organisation>
    <narrative xml:lang="EN">CEPI Secretariat</narrative>
   </organisation>
   <website>https://cepi.net/</website>
  </contact-info>
  <country-budget-items vocabulary="1"></country-budget-items>
  <crs-add>
   <loan-status currency="USD"></loan-status>
  </crs-add>
  <default-aid-type code="B01" vocabulary="1"></default-aid-type>
  <default-finance-type code="110"></default-finance-type>
  <default-flow-type code="10"></default-flow-type>
  <default-tied-status code="5"></default-tied-status>
  <description type="1">
   <narrative xml:lang="EN">CEPI&#x2019;s mission is to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks. The budget presented in this activity includes all investments + operating expenses and financial costs. &#x2022; CFP1 on priority pathogens for EIDs: Launched January 2017 for the diseases Lassa, Nipah and MERS. The decision on priority diseases departed from pathogens identified by the WHO Blueprint for Action, followed by an in-depth assessment by the SAC. In recommending priority diseases to the CEPI Board, the SAC applied criteria related to 1) public health impact (potential of outbreak, transmissibility, burden of disease) and 2) feasibility (current scientific knowledge, pipeline candidates available). &#x2022; CFP2 on platform technologies: Launched October 2017 to enable rapid vaccine development against both known and unknown pathogens that trigger infections with epidemic potential. A requirement is to produce sufficient vaccine doses to impact an emerging outbreak and that the platform demonstrates versatility one of the priority pathogens from the WHO Blueprint list. &#x2022; CEPI&#x2019;s third call for proposals (CfP3i) was for the development of human vaccines against Rift Valley fever and Chikungunya diseases. Rift Valley fever disease is included among the WHO R&amp;D Blueprint list of priority pathogens in 2018, while Chikungunya is deemed to present a major public health risk where further R&amp;D is needed. The call for proposals closed on March, 2019. &#x2022; In addition CEPI has made calls for Biological standards and assays, Data collection and Scientific research. &#x2022; In 2020 CEPI launched a new call for proposals to develop vaccines against novel coronavirus, COVID-19. CEPI will strive to include more details the coming months and years.</narrative>
  </description>
  <document-link format="APPLICATION/PDF" url="https://cepi.net/wp-content/uploads/2019/05/Programme-Document_April-2019.pdf">
   <category code="A02"></category>
   <description>
    <narrative xml:lang="EN">The purpose of this document is to provide coherent overview about this direction as it relates to CEPI&#x2019;s strategic objectives and operations</narrative>
   </description>
   <document-date iso-date="2019-04-30"></document-date>
   <language code="EN"></language>
   <title>
    <narrative xml:lang="EN">Programme Document</narrative>
   </title>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://cepi.net/wp-content/uploads/2019/05/CEPI-Progress-Report_2018.pdf">
   <category code="A08"></category>
   <description>
    <narrative xml:lang="EN">This document provides an overview of CEPI&apos;s activities and achievements in 2018</narrative>
   </description>
   <document-date iso-date="2019-03-31"></document-date>
   <language code="EN"></language>
   <title>
    <narrative xml:lang="EN">Progress Report 2018</narrative>
   </title>
  </document-link>
  <iati-identifier>NO-BRC-917687811-CEPI_01</iati-identifier>
  <participating-org activity-id="DAC-1601-OPP1180343" ref="DAC-1601" role="1" type="60">
   <narrative xml:lang="EN">Bill &amp; Melinda Gates Foundation</narrative>
  </participating-org>
  <participating-org role="1" type="60">
   <narrative xml:lang="EN">wellcome</narrative>
  </participating-org>
  <participating-org activity-id="NO-BRC-971277882_QZA-17/0057" ref="NO-BRC-971277882" role="1" type="10">
   <narrative xml:lang="EN">Norad - Norwegian Agency for Development Cooperation</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Germany</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Japan</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of Belgium</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Australia</narrative>
  </participating-org>
  <participating-org ref="GB-GOV-10" role="1" type="10">
   <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
  </participating-org>
  <participating-org role="4" type="21">
   <narrative xml:lang="EN">International AIDS Vaccine Initiative</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">IDT biologica</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Inovio Pharmaceuticals</narrative>
  </participating-org>
  <participating-org ref="GB-UKPRN-10007774" role="4" type="80">
   <narrative xml:lang="EN">University of Oxford, The</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Themis Bioscience</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Tokyo</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">CureVac</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Imperial College</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Queensland</narrative>
  </participating-org>
  <participating-org ref="US-EIN-91-1157127" role="4" type="21">
   <narrative xml:lang="EN">PATH</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Aurobindo</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Public Health Vaccines</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Emergent BioSolutions</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Colorado State University</narrative>
  </participating-org>
  <participating-org role="4" type="21">
   <narrative xml:lang="EN">International Vaccines Institute</narrative>
  </participating-org>
  <participating-org role="4" type="90">
   <narrative xml:lang="EN">Larissa</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Valneva</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">BNITM</narrative>
  </participating-org>
  <participating-org role="4" type="22">
   <narrative xml:lang="EN">Brighton Collaboration</narrative>
  </participating-org>
  <participating-org role="4" type="11">
   <narrative xml:lang="EN">INRB</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">LSHTM</narrative>
  </participating-org>
  <participating-org role="4" type="22">
   <narrative xml:lang="EN">MSF France</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Antwerpen</narrative>
  </participating-org>
  <participating-org role="4" type="22">
   <narrative xml:lang="EN">Epicentre</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Dalhousie Univesity</narrative>
  </participating-org>
  <participating-org role="4" type="21">
   <narrative xml:lang="EN">FIND</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Janssen</narrative>
  </participating-org>
  <participating-org role="4" type="15">
   <narrative xml:lang="EN">NIBSC</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Tulane University</narrative>
  </participating-org>
  <participating-org role="4" type="15">
   <narrative xml:lang="EN">CDV Mali</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of North-Carolina</narrative>
  </participating-org>
  <participating-org role="4" type="15">
   <narrative xml:lang="EN">Nigeria NCDC</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Benin FORS</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Ethiopia</narrative>
  </participating-org>
  <participating-org role="1" type="90">
   <narrative xml:lang="EN">European Commission</narrative>
  </participating-org>
  <participating-org role="1" type="60">
   <narrative xml:lang="EN">Vulcan</narrative>
  </participating-org>
  <participating-org ref="CA-3" role="1" type="10">
   <narrative xml:lang="EN">Canada - Global Affairs Canada | Affaires mondiales Canada</narrative>
  </participating-org>
  <recipient-region code="998" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">CEPI funds are invested in projects all over the globe. Allthough the companies that we fund may be located in HICs/MICs, the main benificiaries of the products we help develop will be developing countries.</narrative>
  </recipient-region>
  <reporting-org ref="NO-BRC-917687811" type="30">
   <narrative xml:lang="EN">Coalition for Epidemic Preparedness innovations</narrative>
  </reporting-org>
  <sector code="12250" percentage="100" vocabulary="1"></sector>
  <title>
   <narrative xml:lang="EN">Research and development of vaccines</narrative>
  </title>
  <transaction>
   <description>
    <narrative xml:lang="EN">All incoming funds received in 2019</narrative>
   </description>
   <recipient-region vocabulary="1"></recipient-region>
   <transaction-date iso-date="2019-12-31"></transaction-date>
   <transaction-type code="1"></transaction-type>
   <value currency="USD" value-date="2019-12-31"></value>
  </transaction>
  <transaction>
   <description>
    <narrative xml:lang="EN">All incoming funds received in 2018</narrative>
   </description>
   <recipient-region vocabulary="1"></recipient-region>
   <transaction-date iso-date="2018-12-31"></transaction-date>
   <transaction-type code="1"></transaction-type>
   <value currency="USD" value-date="2018-12-31"></value>
  </transaction>
  <transaction>
   <description>
    <narrative xml:lang="EN">All incoming funds received in 2017</narrative>
   </description>
   <recipient-region vocabulary="1"></recipient-region>
   <transaction-date iso-date="2017-12-31"></transaction-date>
   <transaction-type code="1"></transaction-type>
   <value currency="USD" value-date="2017-12-31"></value>
  </transaction>
  <transaction>
   <description>
    <narrative xml:lang="EN">All outgoing investments + Operating expenses and financial costs 2019</narrative>
   </description>
   <recipient-region vocabulary="1"></recipient-region>
   <transaction-date iso-date="2019-12-31"></transaction-date>
   <transaction-type code="3"></transaction-type>
   <value currency="USD" value-date="2019-12-31"></value>
  </transaction>
  <transaction>
   <description>
    <narrative xml:lang="EN">All outgoing investments + Operating expenses and financial costs 2017</narrative>
   </description>
   <recipient-region vocabulary="1"></recipient-region>
   <transaction-date iso-date="2017-12-31"></transaction-date>
   <transaction-type code="3"></transaction-type>
   <value currency="USD" value-date="2017-12-31"></value>
  </transaction>
  <transaction>
   <description>
    <narrative xml:lang="EN">All outgoing investments + Operating expenses and financial costs 2018</narrative>
   </description>
   <recipient-region vocabulary="1"></recipient-region>
   <transaction-date iso-date="2018-12-31"></transaction-date>
   <transaction-type code="3"></transaction-type>
   <value currency="USD" value-date="2018-12-31"></value>
  </transaction>
 </iati-activity>
</iati-activities>
